Stoke Therapeutics (STOK) Total Current Liabilities (2018 - 2026)

Stoke Therapeutics has reported Total Current Liabilities for 9 years, with the latest figure at $40.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 8.68% year-over-year to $40.8 million; the trailing twelve-month figure through Mar 2026 stood at $40.8 million (down 8.68% YoY), and the FY2025 full-year result was $57.9 million, up 44.49% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $40.8 million, down from $57.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $57.9 million in Q4 2025, with the low at $21.8 million in Q2 2023.
• Average Total Current Liabilities over 5 years is $36.1 million, with a median of $35.6 million recorded in 2024.
• Year-over-year, Total Current Liabilities jumped 274.88% in 2022 and slipped 21.02% in 2023.
• Tracing STOK's Total Current Liabilities over 5 years: stood at $31.4 million in 2022, then decreased by 1.83% to $30.8 million in 2023, then climbed by 29.97% to $40.1 million in 2024, then surged by 44.49% to $57.9 million in 2025, then fell by 29.49% to $40.8 million in 2026.
• The last three Total Current Liabilities figures came in at $40.8 million (Q1 2026), $57.9 million (Q4 2025), and $41.7 million (Q3 2025), per Business Quant data.

Peer Comparison